Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of DCR-PHXC in primary hyperoxaluria
MOH_2019-06-25_007228Phase 2Completed
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Apr 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary hyperoxaluria (PH) comparing DCR-PHXC with Placebo (2 arms). Primary endpoint: Efficacy. Started Apr 2019; status: completed.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on MOH_2019-06-25_007228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-25_007228.